New York, Feb 10, 2026, 14:31 EST — Regular session
- Abbott shares climbed roughly 1.5% in afternoon trading, outperforming the flat healthcare sector.
- New data on atrial fibrillation devices grabbed fresh attention at last week’s AF Symposium in Boston.
- Investors are closely monitoring any fallout from Abbott’s recall and scrutiny of its diabetes sensors.
Abbott Laboratories shares climbed roughly 1.5% to $112.68 on Tuesday, fluctuating between $110.74 and $112.75 during the session. Trading volume hit about 4.4 million shares, matching the stock’s usual activity by mid-afternoon.
This move is significant as Abbott works to recover after its January report, which saw the company miss quarterly revenue forecasts and highlight struggles in nutrition and diagnostics. That, in turn, increased pressure on its medical-devices pipeline to deliver.
Traders highlighted fresh clinical updates emerging from the 2026 AF Symposium, where major cardiac-device manufacturers unveiled late-breaking data on atrial fibrillation technologies and stroke-prevention implants.
On Feb. 6, Abbott shared early findings from its VERITAS study on the experimental Amulet 360 left atrial appendage occluder—a device designed to seal off a tiny heart pouch where clots often form in patients with atrial fibrillation. The company reported that 93.9% of patients achieved complete closure at 45 days. Follow-up for the trial is expected to wrap up in 2027.
Just a day later, MedTech Dive reported that Abbott shared one-year results for its Volt pulsed field ablation (PFA) system, alongside six-month data on its TactiFlex Duo catheter. The Volt study revealed an 84.2% freedom-from-recurrence rate in paroxysmal AFib at one year. Abbott also detailed how the device compares to newer PFA systems from bigger competitors.
Tuesday saw a mostly steady vibe among big medtech names. Johnson & Johnson climbed roughly 0.6%, Medtronic inched up about 0.5%, and Boston Scientific ticked higher by around 0.6%.
The strength wasn’t driven by any major sector boost. The Health Care Select Sector SPDR Fund barely moved, while the SPDR S&P 500 ETF edged down slightly.
PFA is a newer ablation technique that employs electrical pulses to shut down heart tissue causing irregular rhythms, instead of relying on heat or cold. Hospitals are increasingly adopting it since the procedures tend to be quicker and more precise, though the market is becoming more competitive.
Abbott’s immediate challenges extend beyond cardiac devices. The company is also dealing with the repercussions of a recall involving certain FreeStyle Libre glucose sensors. The U.S. FDA flagged company data indicating serious injuries tied to inaccurate readings, resulting in a Class I recall.
Investors will soon turn their attention to Abbott’s upcoming earnings report on April 22. They’ll be looking for insights into nutrition demand, the latest in diabetes care, and how quickly Volt’s commercial rollout is progressing.
Until that point, the stock’s movement will hinge on smaller triggers — like buzz from conferences, new regulatory news around diabetes sensors, and whether hospitals continue investing in PFA systems as their 2026 purchasing plans take shape.
